Mizuho Reiterates Buy Rating for ASMB, Sets $45 Price Target
Mizuho reiterates its Buy rating on ASMB, aiming for a $45 target.
Key Points
- Mizuho reiterated its Buy rating on ASMB with a $45 price target on June 15, 2026.
- ASMB shares are trading at $22.96, with recent insider buying activity noted.
- Peer funds like Janus Henderson increased their ASMB holdings, while other funds maintained their positions.
On June 15, 2026, Mizuho reiterated its Buy rating on ASMB, setting a price target of $45. Analyst Salim Syed emphasized confidence in the stock's potential, with ASMB currently trading at $22.96.
Other Institutional Activity in ASMB
Janus Henderson Group PLC increased its holdings in ASMB by 11,384 shares, ending with 849,309 shares valued at approximately $23.48 million. Meanwhile, other major funds like Gilead Sciences, Inc., Farallon Capital Management LLC, and RA Capital Management, L.P., held steady with their positions, maintaining their share counts at 4,505,391, 1,227,590, and 1,020,410 shares respectively.
ASMB Stock Snapshot
ASMB shares are currently trading at $22.96. The stock has seen various analyst activities, with a notable Buy rating and a target price of $45 from Mizuho. This reflects confidence from analysts and investors despite the current trading price.
Insider Buying and Selling at Assembly Biosciences, Inc.
Several insiders, including John McHutchison, Susan Mahony, and Anthony Altig, each purchased 8,000 shares of ASMB on June 4, 2026. These transactions were not part of a pre-planned trading program, indicating personal confidence in the company's prospects.
Analysts Set New Price Targets
On June 15, 2026, Mizuho maintained its Buy rating on ASMB with a $45 price target. Earlier, on April 6, 2026, Guggenheim also maintained a Buy rating with a $43 target. Furthermore, HC Wainwright & Co. reiterated a Buy rating on March 26, 2026, with a higher target of $50. The consensus among analysts is a strong Buy recommendation.
About ASMB
ASMB operates in the biotechnology sector, focusing on developing innovative therapies for various diseases. The company is headquartered in the United States and works on advancing treatments that address unmet medical needs.
Bottom Line
Mizuho's reaffirmed Buy rating and $45 price target for ASMB highlight the firm's positive outlook on the stock. With ASMB trading at $22.96 and insider buying activity, there is interest in the company's future potential. It's important to remember that these analyst ratings and price targets are based on current data and can change over time.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.